BLTE BELITE BIO, INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$161.08

Period return

+1.23 (+0.77%)

Volume

175.2K

2026-07-21O $152.67 H $161.21 L $151.35 C $161.08MA5 $152.83MA20 $150.82MA60 $148.42MA120 $159.71

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 10.Highin 20 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 27.LowBUY2 months ago
Mizuho: Outperform
US analyst rating / recommendation change.
2026. 05. 21.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 04. 22.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 04. 13.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 04.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 04.LowBUY5 months ago
Morgan Stanley: Overweight
US analyst rating / recommendation change.
2026. 03. 03.LowBUY5 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2026. 01. 28.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 26.MediumBUY6 months ago
B of A Securities: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $210.5 · 8 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Sector: Healthcare
Industry: Biotechnology
HQ: San Diego, CA, United States
Fiscal year end: —
Employees: 41
IPO date: —

View details →

BELITE BIO, INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 27.	Mizuho	—	Maintain	Outperform → Outperform	—	Mizuho: Outperform
2026. 05. 21.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 04. 22.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 04. 13.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 04.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 04.	Morgan Stanley	—	Maintain	Overweight → Overweight	—	Morgan Stanley: Overweight